Your Unread Messages
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer
European Urology, 11/03/09
Dalbagni G et al. – Conservative management of clinical T1 bladder cancer depends on careful selection and monitoring of patients. All patients being considered for conservative management should undergo restaging transurethral resection to allow for better risk assessment. Patients with T1 disease on restaging are at high risk of progression and should be considered for early cystectomy.
Related Articles
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
BMC Cancer, 11/13/09
Relevance Score: 70%
Evidence-based Principles of Bladder Cancer and Diet
Urology, 10/21/09
Relevance Score: 70%
Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09
Relevance Score: 70%
Biomarkers in bladder cancer
BJU International, 10/01/09
Relevance Score: 70%
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 70%
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Prospective Study of Transcutaneous Parasacral Electrical Stimulation for Overactive Bladder in Children: Long-Term Results
The Journal of Urology, 11/24/09
Transfer of cysto-urethroscopy skills from a virtual-reality simulator to the operating room: a randomized controlled trial
BJU International, 11/24/09
The Boari bladder flap: an effective continent stoma for the high-compliance neurogenic bladder
BJU International, 11/24/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
Journal of Clinical Oncology, 11/24/09
Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary Score
The Journal of Urology, 11/24/09
Article Search
Sponsor


See All


